What is RANI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RANI?

P/E (TTM) is n/a and 52-week range is $0.57 to $2.63 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RANI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RANI?

The company profile lists revenue (TTM) near $4M, net income (TTM) near -$1.84B, EPS (TTM) near -$0.26 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rani Therapeutics Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Jose, California, US, 139.4M shares outstanding, ISIN US7530181004 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Rani Therapeutics Holdings Inc

$RANI

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 69 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Employees

Website

www.ranitherapeutics.com

IPO

2021-07-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US7530181004

Headquarters

San Jose, California, US

Shares outstanding

139.4M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

44.50%

Browse other companiesFree AI scores and summaries for more stocks